NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PRPO
Precipio, Inc.
There isn't enough reported data to score PRPO yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
PRPO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Healthy | |
| Strong |
PRPO's revenue, cash flow and balance sheet are currently healthy, but its profitability is under pressure.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
PRPO PE Valuation
PRPO has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
PRPO Forward outlook
There aren't enough analyst estimates for PRPO to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over PRPO on earnings quality, reporting a profit while its opponent remains loss making.
PRPO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.57 | +$0.24 |
| Q2 2026 | -$0.62 | +$0.56 |
| Q1 2026 | -$0.45 | +$1.61 |
| Q4 2025 | -$0.23 | +$2.70 |
| Q3 2025 | -$0.81 | +$1.24 |
| Q2 2025 | -$1.18 | +$1.49 |
| Q1 2025 | -$2.06 | +$1.58 |
| Q4 2024 | -$2.93 | +$1.85 |
PRPO is still losing money, but far less than before: $0.57 per share over the past year, against $52.60 at its worst in early 2020.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over PRPO on profitability, with a higher operating margin.
PRPO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.3M | +8.3% |
| Q2 2026 | $7M | +24% |
| Q1 2026 | $6.7M | +36% |
| Q4 2025 | $6.7M | +23% |
| Q3 2025 | $6.8M | +30% |
| Q2 2025 | $5.7M | +27% |
| Q1 2025 | $4.9M | +44% |
| Q4 2024 | $5.5M | +26% |
PRPO has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 0% | +0.9 points |
| Q2 2026 | -8.5% | +6 points |
| Q1 2026 | -21% | -3.9 points |
| Q4 2025 | 8.1% | +14 points |
| Q3 2025 | -0.9% | +11 points |
| Q2 2025 | -15% | +13 points |
| Q1 2025 | -17% | +43 points |
| Q4 2024 | -6.2% | +14 points |
PRPO's operating margin was 0% last quarter, up 0.9 points from the same quarter a year ago, near the top of its range since 2019.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO still generates free cash flow, though less than at its 2026 peak: $7.3B over the past year.
PRPO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $554K | +$598K |
| Q2 2026 | $528K | +80% |
| Q1 2026 | $14K | +$196K |
| Q4 2025 | $291K | -44% |
| Q3 2025 | -$44K | +$24K |
| Q4 2024 | $521K | +702% |
| Q3 2024 | -$68K | +$851K |
| Q4 2023 | $65K | +$1.6M |
PRPO has the edge over NVO on cash flow, with more consistent year-over-year improvement.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over PRPO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
PRPO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +3.5K shares |
| 1 year | +9.4% | +153K shares |
| 3 years | +28% | +396K shares |
| 5 years | +58% | +655K shares |
| Available history | +529% | +1.5M shares |
PRPO has 2M diluted shares, up 9.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
PRPO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | -59.9x | Net Cash |
PRPO has more cash than debt.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
PRPO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 49.6 | Neutral |
| Stochastic | 14.4 | Oversold |
PRPO's weekly RSI is 50 (neutral) and its Stochastic is 14 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PRPO PE vs Healthcare Sector
PRPO has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
PRPO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.4 | 8.6% above |
| 20 week MA | $23.9 | 2.8% below |
| 50 week MA | $24.6 | 5.3% below |
| 100 week MA | $18.2 | 27% above |
| 200 week MA | $13.1 | 78% above |
PRPO has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.
PRPO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.8 | $41.8 | +2.5% |
| 2021 | $41.8 | $35.6 | -15% |
| 2022 | $35.6 | $11.0 | -69% |
| 2023 | $11.0 | $6.50 | -41% |
| 2024 | $6.50 | $5.51 | -15% |
| 2025 | $5.51 | $23.8 | +331% |
| 2026 YTD | $23.8 | $23.3 | -2.1% |
PRPO has the edge over NVO on returns for 2026, with the stronger performance.